Puma Biotechnology (PBYI) Depreciation & Amortization (CF) (2011 - 2026)

Puma Biotechnology's Depreciation & Amortization (CF) history runs 16 years deep, the most recent figure standing at $2.6 million for Q1 2026.

• Quarterly Depreciation & Amortization (CF) fell 7.58% year-over-year to $2.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $10.7 million (down 6.1% YoY) and the FY2025 annual result came in at $10.9 million, down 5.09% from the prior year.
• Depreciation & Amortization (CF) was $2.6 million for Q1 2026 at Puma Biotechnology, down from $2.7 million in the prior quarter.
• Across five years, Depreciation & Amortization (CF) topped out at $2.9 million in Q2 2024 and bottomed at $2.5 million in Q4 2022.
• A 5-year average of $2.7 million and a median of $2.8 million in 2025 frame the typical range for Depreciation & Amortization (CF).
• Annual changes were most pronounced in 2022 — Depreciation & Amortization (CF) retreated 17.63% — and 2023, when it climbed 17.77%.
• Puma Biotechnology's Depreciation & Amortization (CF) stood at $2.5 million in 2022, then increased by 17.77% to $2.9 million in 2023, then declined by 1.66% to $2.8 million in 2024, then dropped by 6.48% to $2.7 million in 2025, then slipped by 2.75% to $2.6 million in 2026.
• Business Quant data shows PBYI's Depreciation & Amortization (CF) at $2.6 million in Q1 2026, $2.7 million in Q4 2025, and $2.7 million in Q3 2025.